Research programme: CNS disorder therapeutics - Aprecia Pharmaceuticals

Drug Profile

Research programme: CNS disorder therapeutics - Aprecia Pharmaceuticals

Alternative Names: Oxcarbazepine - Aprecia Pharmaceuticals; Product 2 - Aprecia Pharmaceuticals; Product 3 - Aprecia Pharmaceuticals; Product 4 - Aprecia Pharmaceuticals

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aprecia Pharmaceuticals
  • Class Dibenzazepines; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical CNS disorders

Most Recent Events

  • 13 Dec 2017 Aprecia Pharmaceuticals enters into a partnership with Cycle Pharmaceuticals for development of orphan drugs
  • 16 Jul 2015 Aprecia has patent protection for oxcarbazepine and levetiracetam
  • 16 Jul 2015 Aprecia Pharmaceuticals plans regulatory submissions for CNS disorders (Aprecia Pharmaceuticals pipeline, July 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top